OpenLB
Open Library of Bioscience
Advanced Search
Pharmaceutical research
Oct, 2017;34 (10): 1985-1999.

Reflections on the Future of Pharmaceutical Public-Private Partnerships: From Input to Impact.

Remco L A de Vrueh, Daan J A Crommelin
Author Information
  1. Remco L A de Vrueh: Lygature, Utrecht, The Netherlands.
  2. Daan J A Crommelin: Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, UIPS, Utrecht University, Utrecht, The Netherlands. d.j.a.crommelin@uu.nl. ORCID
PMID: 28589444 DOI: 10.1007/s11095-017-2192-5

Abstract

Public Private Partnerships (PPPs) are multiple stakeholder partnerships designed to improve research efficacy. We focus on PPPs in the biomedical/pharmaceutical field, which emerged as a logical result of the open innovation model. Originally, a typical PPP was based on an academic and an industrial pillar, with governmental or other third party funding as an incentive. Over time, other players joined in, often health foundations, patient organizations, and regulatory scientists. This review discusses reasons for initiating a PPP, focusing on precompetitive research. It looks at typical expectations and challenges when starting such an endeavor, the characteristics of PPPs, and approaches to assessing the success of the concept. Finally, four case studies are presented, of PPPs differing in size, geographical spread, and research focus.

Keywords

R&D business models key drivers performance evaluation public-private-partnerships

References

  1. Proc Biol Sci. 2015 Dec 22;282(1821):20151684 [PMID: 26702037]
  2. Nat Rev Drug Discov. 2014 Jun;13(6):406 [PMID: 24875086]
  3. Ther Innov Regul Sci. 2016 Jan;50(1):44-48 [PMID: 30236007]
  4. Am J Med. 2003 Apr 15;114(6):503-5 [PMID: 12727585]
  5. Alzheimers Dement. 2015 Jul;11(7):860-4 [PMID: 26194319]
  6. Nat Rev Drug Discov. 2011 Aug 01;10(8):559-60 [PMID: 21804580]
  7. Sci Transl Med. 2016 Apr 27;8(336):336ps11 [PMID: 27122611]
  8. Sci Transl Med. 2014 Jun 25;6(242):242cm6 [PMID: 24964986]
  9. Science. 2005 Jul 29;309(5735):726 [PMID: 16051784]
  10. Res Synth Methods. 2016 Sep;7(3):264-77 [PMID: 27529762]
  11. Lancet. 2013 Jun 15;381(9883):2072 [PMID: 23776961]
  12. Sci Transl Med. 2014 Jun 25;6(242):242ed15 [PMID: 24964987]
  13. Travel Med Infect Dis. 2004 Aug-Nov;2(3-4):161-70 [PMID: 17291977]
  14. Nat Med. 2010 Aug;16(8):837 [PMID: 20689537]
  15. Drug Discov Today. 2014 Nov;19(11):1711-1720 [PMID: 24657626]
  16. Aust New Zealand Health Policy. 2007 Jun 28;4:14 [PMID: 17597545]
  17. Alzheimer Dis Assoc Disord. 2006 Jul-Sep;20(3 Suppl 2):S58-62 [PMID: 16917197]
  18. Philos Trans A Math Phys Eng Sci. 2011 May 13;369(1942):1817-25 [PMID: 21464073]
  19. Clin Pharmacol Ther. 2007 Jan;81(1):129-33 [PMID: 17186012]
  20. Health Res Policy Syst. 2015 Mar 18;13:18 [PMID: 25884944]
  21. Expert Opin Drug Discov. 2014 Jan;9(1):1-8 [PMID: 24308355]
  22. Health Aff (Millwood). 2004 Jan-Feb;23(1):10-22 [PMID: 15002624]
  23. J Health Econ. 2013 Jan;32(1):106-13 [PMID: 23220457]
  24. Drug Discov Today. 2013 Dec;18(23-24):1133-7 [PMID: 23892183]
  25. Arch Neurol. 2011 Jan;68(1):19-21 [PMID: 21220673]
  26. Alzheimers Dement. 2015 Jul;11(7):865-84 [PMID: 26194320]
  27. Science. 2013 Jun 21;340(6139):1375 [PMID: 23788767]
  28. Sci Transl Med. 2013 Dec 18;5(216):216ed22 [PMID: 24353157]
  29. JAMA. 2003 Jan 22-29;289(4):454-65 [PMID: 12533125]
  30. Nat Rev Drug Discov. 2009 Dec;8(12):959-68 [PMID: 19949401]
  31. Healthc Manage Forum. 2001 Winter;14(4):44-9 [PMID: 11855210]
  32. Nat Rev Drug Discov. 2004 Aug;3(8):711-5 [PMID: 15286737]
  33. Nature. 2016 Aug 24;536(7617):388-90 [PMID: 27558048]
  34. Lancet. 2016 Nov 19;388(10059):2457-2459 [PMID: 27871734]
  35. Int Dent J. 2011 Aug;61 Suppl 2:2-10 [PMID: 21770935]
  36. Cell. 2016 May 5;165(4):765-70 [PMID: 27153487]
  37. Oncologist. 2014 Nov;19(11):1113-4 [PMID: 25326160]
  38. Nat Rev Drug Discov. 2005 Nov;4(11):891-7 [PMID: 16247439]
  39. J Clin Epidemiol. 2010 Sep;63(9):945-9 [PMID: 20573481]
  40. Res Involv Engagem. 2015 Jun 25;1:5 [PMID: 29062494]
  41. Biotechnol Law Rep. 2015 Aug 1;34(4):153-165 [PMID: 26396462]
  42. Nature. 2016 Mar 17;531(7594):299-301 [PMID: 26983524]
  43. Rand Health Q. 2014 Dec 30;4(3):19 [PMID: 28560088]
  44. Bull World Health Organ. 2001;79(8):728-34 [PMID: 11545329]
  45. Drug Discov Today. 2015 Mar;20(3):361-70 [PMID: 25448753]
  46. Nat Rev Drug Discov. 2012 Mar 01;11(3):191-200 [PMID: 22378269]
  47. Regen Med. 2010 Sep;5(5):687-90 [PMID: 20868323]
  48. BMC Med. 2015 Sep 21;13:232 [PMID: 26391108]
  49. Soc Sci Med. 2008 May;66(9):1909-14 [PMID: 18299169]
  50. Nat Rev Drug Discov. 2007 Feb;6(2):99-101 [PMID: 17342860]
  51. Alzheimers Dement. 2009 May;5(3):271-5 [PMID: 19362888]
  52. Front Pharmacol. 2016 Dec 06;7:461 [PMID: 27999543]
  53. Clin Transl Med. 2013 Jan 15;2(1):2 [PMID: 23369569]
  54. Front Pharmacol. 2016 Sep 28;7:305 [PMID: 27733828]
  55. Alzheimers Dement. 2015 Jul;11(7):850-9 [PMID: 26194318]
  56. BMJ. 2003 May 31;326(7400):1167-70 [PMID: 12775614]
  57. Clin Pharmacol Ther. 2010 Mar;87(3):356-61 [PMID: 20130565]
  58. Nat Rev Drug Discov. 2012 Mar 30;11(5):419 [PMID: 22460037]
  59. Annu Rev Med. 2008;59:1-12 [PMID: 18186700]
  60. BMC Med. 2011 Sep 01;9:101 [PMID: 21884605]
  61. Transl Res. 2011 Jan;157(1):1-5 [PMID: 21146144]
  62. N Engl J Med. 1996 Feb 8;334(6):368-73 [PMID: 8538709]
  63. Alzheimers Dement. 2012 Jul;8(4):337-42 [PMID: 22748939]
  64. Soc Sci Med. 2011 Oct;73(7):986-94 [PMID: 21839562]
  65. N Engl J Med. 1996 Dec 5;335(23):1734-9 [PMID: 8929266]
  66. Trans R Soc Trop Med Hyg. 2005 Oct;99 Suppl 1:S9-14 [PMID: 16087204]
  67. Clin Pharmacol Ther. 2012 Mar;91(3):418-25 [PMID: 22318619]
  68. Alzheimers Dement. 2014 Nov;10(6):873-80 [PMID: 25218016]
  69. J Control Release. 2012 Jul 20;161(2):416-21 [PMID: 22465390]
  70. Eur J Immunol. 2013 Feb;43(2):298-302 [PMID: 23534061]
  71. Sci Transl Med. 2015 Jun 10;7(291):291fs25 [PMID: 26062844]
  72. Pharmacoepidemiol Drug Saf. 2016 Mar;25 Suppl 1:5-10 [PMID: 27038353]
  73. J Intern Med. 2014 Mar;275(3):251-83 [PMID: 24605808]
  74. Nat Rev Drug Discov. 2015 Jan;14(1):1-2 [PMID: 25503331]
  75. J Transl Med. 2016 Apr 27;14(1):105 [PMID: 27118048]
  76. N Engl J Med. 2013 Mar 28;368(13):1169-71 [PMID: 23484795]
  77. Soc Sci Med. 2007 Jan;64(2):259-71 [PMID: 17055633]
  78. Trans R Soc Trop Med Hyg. 2005 Oct;99 Suppl 1:S1-8 [PMID: 16085172]
  79. Respir Care. 2009 Jun;54(6):788-95; discussion 795 [PMID: 19467165]
  80. PLoS One. 2015 Apr 02;10(4):e0122239 [PMID: 25837969]
  81. Alzheimers Dement. 2013 Jul;9(4):466-71 [PMID: 23809367]
  82. Clin Pharmacol Ther. 2015 Mar;97(3):221-33 [PMID: 25670629]

MeSH Term

Drug Industry
Foundations
Humans
Organizations
Public-Private Sector Partnerships
Research
Universities
Journal Article Review
Article has an altmetric score of 31

Word Cloud

Created with Highcharts 10.0.0PPPsresearchfocustypicalPPPPublicPrivatePartnershipsmultiplestakeholderpartnershipsdesignedimproveefficacybiomedical/pharmaceuticalfieldemergedlogicalresultopeninnovationmodelOriginallybasedacademicindustrialpillargovernmentalthirdpartyfundingincentivetimeplayersjoinedoftenhealthfoundationspatientorganizationsregulatoryscientistsreviewdiscussesreasonsinitiatingfocusingprecompetitivelooksexpectationschallengesstartingendeavorcharacteristicsapproachesassessingsuccessconceptFinallyfourcasestudiespresenteddifferingsizegeographicalspreadReflectionsFuturePharmaceuticalPublic-PrivatePartnerships:InputImpactR&Dbusinessmodelskeydriversperformanceevaluationpublic-private-partnerships

Similar Articles

Cited By